Linagliptin Viatris

Linagliptin, the active ingredient in Linagliptin Viatris, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as a tablet for oral use. It treats type 2 diabetes mellitus in adult patients, helping to improve glycaemic control when used with diet and exercise.

GNH USA supplies Linagliptin Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptin is a DPP‑4 inhibitor used in the management of type 2 diabetes mellitus.

Type 2 diabetes mellitus (monotherapy): improves blood glucose control as a single oral agent. Type 2 diabetes mellitus (combination therapy): enhances glycaemic control when added to metformin, sulfonylureas or insulin. Type 2 diabetes mellitus (renal impairment): can be used without dose adjustment, providing an option for patients with reduced kidney function.

Common Side Effects: - Upper respiratory tract infection: mild symptoms such as sore throat or nasal congestion. - Nasopharyngitis: inflammation of the nasal passages and throat. - Headache: transient mild to moderate headache. - Gastrointestinal discomfort: occasional nausea or abdominal pain. - Dizziness: brief episodes of light‑headedness.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe hypersensitivity reactions: rash, angioedema or anaphylaxis. - Hypoglycaemia (when combined with insulin or sulfonylureas): low blood sugar episodes. - Hepatic injury: elevated liver enzymes or jaundice. - Acute kidney injury: rare but possible decline in renal function. - Bullous skin eruptions: blistering skin reactions.

Before prescribing Linagliptin, clinicians should consider the following precautions.

Renal impairment: no dose adjustment needed, but monitor renal function regularly. Hepatic impairment: use with caution in patients with moderate to severe liver disease. Pregnancy: Category B; prescribe only if the potential benefit justifies the potential risk to the fetus. Elderly patients: monitor for hypoglycaemia, especially when used with insulin or sulfonylureas. Drug interactions: review concomitant medications for agents that may affect glucose levels. Store at ambient temperature: keep in the original container, protect from moisture and light.

Linagliptin may interact with several co‑administered medicines.

Major Interactions (Avoid): - Insulin or sulfonylureas: increased risk of hypoglycaemia. - Strong P‑glycoprotein inhibitors (e.g., itraconazole): may raise linagliptin exposure.

Moderate Interactions (Monitor Closely): - Rifampin: may reduce linagliptin plasma concentrations. - Diuretics: may affect glucose homeostasis, requiring closer monitoring. - ACE inhibitors: watch for additive blood pressure effects.